Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

HM61713

  • Zoom
    HM61713
  • HM61713
Cat No: 19481
Biochemicals - Kinase Inhibitors
Cayman
€33.00
Price is excluding VAT and does not include packaging neither shipping

HM61713 is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR.{32030,32031} It has been investigated in Phase II clinical...

More

This product can only be bought through Cayman Chemical. Please contact us.

- +
Territorial Availability: Available through Bertin Pharma only in Europe
Synonyms:
  • N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide
Correlated keywords:
  • 1842366-97-5 HM-61713 BI1482694 EGFR epidermal growth factor receptor tyrosine kinase T790M T-790M T-790-M T790-M third generation
Product Overview:
HM61713 is a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR.{32030,32031} It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy.{32031}
Size 1 mg
Shipping dry ice
Stability Store at -20 degrees; shelf life 730 days
CAS Number 1353550-13-6
Molecular Formula C26H26N6O2S
SMILES CN1CCN(C2=CC=C(NC3=NC(OC4=CC=CC(NC(C=C)=O)=C4)=C(SC=C5)C5=N3)C=C2)CC1
Molecular Weight 486,6
Formulation A crystalline solid
Purity ≥98%
Custom Code 2933.59
UNSPSC code 12352100

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : HM61713 There are 5 products.

Search